Goldman Sachs Group Analysts Give GlaxoSmithKline (GSK) a GBX 1,775 Price Target

Goldman Sachs Group set a GBX 1,775 ($23.77) target price on GlaxoSmithKline (LON:GSK) in a research note issued to investors on Friday morning. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Liberum Capital restated a buy rating and issued a GBX 1,900 ($25.45) price target on shares of GlaxoSmithKline in a report on Wednesday, August 30th. Jefferies Group lowered their price target on GlaxoSmithKline from GBX 1,900 ($25.45) to GBX 1,750 ($23.44) and set a buy rating for the company in a report on Thursday, August 24th. Berenberg Bank lowered their price target on GlaxoSmithKline from GBX 1,885 ($25.24) to GBX 1,835 ($24.57) and set a buy rating for the company in a report on Wednesday, August 9th. restated a buy rating and issued a GBX 1,970 ($26.38) price target on shares of GlaxoSmithKline in a report on Wednesday, September 13th. Finally, Beaufort Securities restated a buy rating and issued a GBX 1,800 ($24.11) price target on shares of GlaxoSmithKline in a report on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of GBX 1,581.90 ($21.19).

Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,295 ($17.34) on Friday. GlaxoSmithKline has a fifty-two week low of GBX 1,277.50 ($17.11) and a fifty-two week high of GBX 1,724.50 ($23.09).

GlaxoSmithKline (LON:GSK) last announced its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The company had revenue of GBX 784.30 billion during the quarter.

The company also recently disclosed a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.

In other news, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.33) per share, for a total transaction of £7,180.14 ($9,615.83). Also, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.45) per share, with a total value of £16,430.52 ($22,004.18). Over the last quarter, insiders have purchased 1,576 shares of company stock valued at $2,400,376.

COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group Analysts Give GlaxoSmithKline (GSK) a GBX 1,775 Price Target” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/12/04/goldman-sachs-group-analysts-give-glaxosmithkline-gsk-a-gbx-1775-price-target.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit